BRF2

Across TCGA pan-cancer cohorts, BRF2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BRF2 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BRF2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BRF2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where BRF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.458	0.781	.002	49	view →
LUAD	OS	Tertile	All	0.777	1.000	.044	1	view →
CCRCC	DFS	Quartile	All	0.865	0.584	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

BRF2–HNSC (OS)

Open the HNSC breakdown →